

Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022

<https://marketpublishers.com/r/GCE9E151C93EEN.html>

Date: December 2021

Pages: 120

Price: US\$ 3,300.00 (Single User License)

ID: GCE9E151C93EEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022 Report Highlights:

Global TIGIT Inhibitor Market Dynamics

Clinical Approaches to Target TIGIT

Role of TIGIT Inhibitors in Cancer, HIV, Autoimmune Disorders

Number of TIGIT Inhibitor Drug In Trials

TIGIT Inhibitors Trials By Phase, Company, Country, Indication

Clinical Trials Adverse Events Scenario

Company Agreement/Partnership/Deals For Ongoing Trials

Global TIGIT Inhibitor Market Future Outlook

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recently identified immune checkpoint inhibitor which is being evaluated as potential immunotherapeutic target. TIGIT is transmembrane glycoprotein receptor with Ig-like V-type domain and an ITIM in its cytoplasmic domain and is expressed on wide range of

cells including memory T-cells, NK cells, and Tregs. Apart from this, studies have demonstrated high expression of TIGIT on wide range of solid tumors and hematological malignancies, thus making it potential target in drug development.

Several pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors in their pipeline indicated for the management of several cancers. Current clinical trials are mainly evaluating the role of TIGIT inhibitors in combination with PD-1/PD-L1 inhibitor or CTLA-4 inhibitors. Immunotherapy combinations featuring dual blockade of TIGIT and PD-1/PD-L1 are promising due to their synergistic enhancement of antitumor responses. More recently, Compugen in collaboration with Bristol Meyer Squibb is evaluating triple combination of Opdivo, BMS-986207 (anti-TIGIT), and COM701 (anti-PVRIG). The preliminary data suggest that the triple combination was safe and well tolerated.

Apart from cancer, researchers are also evaluating the role of novel immune checkpoint in other therapeutic conditions including HIV and autoimmune disorders. TIGIT has emerged out to be attractive target in HIV due to its expression on NK cells and almost all HIV-specific CD8+ T cells. Preclinical studies have favored the co-blockade of TIGIT with PD-1/PD-L1 inhibitor in HIV patients. The encouraging response from preclinical trials is expected to be translated in clinical studies in coming years. Further, researchers have also suggested the relationship between TIGIT expressing Treg cells and different autoimmune diseases including atopic dermatitis, autoimmune thyroiditis, type-1 diabetes, autoimmune uveitis, aplastic anemia, multiple sclerosis, systemic lupus erythematosus, arthritis, and colitis. As of now, these studies are mainly confined to in-vivo and preclinical studies.

Currently, the market for TIGIT inhibitor is mainly domination by therapeutic monoclonal antibodies. Several monoclonal antibodies targeting TIGIT have entered the clinical development including Tiragolumab, Ociperlimab, Vibostolimab, ASP-8374, and COM902. Further enhancement in the field of biotechnology and promising results of TIGIT inhibitor in combinational therapies have led to the development of novel bispecific constructs. Currently, a few bispecific antibodies including AGEN1777, IBI321 and HLX301 have entered initial stages of clinical trials. The emergence of bispecific antibody constructs is expected to show enhanced efficacy and will reduce the overall cost of therapy and drug development.

Globally, there are more than 30 clinical trials ongoing which are evaluating novel anti-TIGIT antibodies in wide range of diseases. Some of the major indications which are anticipated to show a better outcome by the launch of these drugs include triple

negative breast cancer, non-small cell lung cancer, colorectal cancer, melanoma, gastric cancer, and esophageal cancer. The global market is anticipated to show positive growth due to launch of TIGIT therapies during forthcoming years. Tiragolumab developed by Roche is leading drug candidate which has received priority review by US FDA and is expected to be launched in market by 2022. The emerging trend in TIGIT next generation immunotherapies with continuous headway movement along with the development of new technologies for the development of targeted therapies provides hope for better therapeutic alternatives in coming years.

US will dominate the TIGIT Inhibitor development and commercialization landscape which is mainly attributed to large number of ongoing clinical trials in the region. Further, the high concentration of key players in the region which actively invest in research and development will also propel the growth of market. Beside US, China and South Korea will also emerge as key markets for TIGIT inhibitors drugs driven by increasing research and development activities.

Contents

1. INTRODUCTION TO TIGIT INHIBITOR

- 1.1 Overview
- 1.2 Historical Perspective

2. ROLE OF TIGIT INHIBITORS IN CANCER

- 2.1 Enhanced Anti-Tumor Effects
- 2.2 Reduced Immunosuppressive Functions
- 2.3 Augments Anti-Tumor Immunity

3. ROLE OF TIGIT INHIBITORS IN HIV

4. ROLE OF TIGIT IN AUTOIMMUNE DISORDERS

5. MECHANISM OF TIGIT INHIBITOR

6. CLINICAL APPROACHES TO TARGET TIGIT

- 6.1 Therapeutic Monoclonal Antibodies
- 6.2 Bispecific Antibodies
- 6.3 Small Molecule Inhibitors

7. FDA ORPHAN DESIGNATION FOR TIRAGOLUMAB

8. GLOBAL TIGIT INHIBITORS CLINICAL TRIALS OVERVIEW

- 8.1 By Company
- 8.2 By Country
- 8.3 By Patient Segment

9. GLOBAL TIGIT INHIBITORS CLINICAL TRIALS INSIGHT 2022

- 9.1 Research
- 9.2 Preclinical
- 9.3 Phase-I

9.4 Phase-I/II

9.5 Phase-II

9.6 Phase-III

10. GLOBAL TIGIT INHIBITOR MARKET DYNAMICS

10.1 Market Drivers

10.2 Commercialization Challenges

11. GLOBAL TIGIT INHIBITOR MARKET FUTURE OUTLOOK

12. COMPETITIVE LANDSCAPE

12.1 Acrus Biosciences

12.2 Agensus

12.3 Astellas Pharma

12.4 AstraZeneca

12.5 Beigene

12.6 Bristol Meyer Squibb

12.7 Compugen

12.8 Gilead Sciences

12.9 iTeos Therapeutics

12.10 Merck

12.11 Roche

12.12 Seagen

12.13 Seattle Genetics

12.14 Shanghai Helnius Biotech

List Of Figures

LIST OF FIGURES

- Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
- Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT & PD-1 Blockade
- Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
- Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
- Figure 3-1: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
- Figure 4-1: TIGIT Associated Autoimmune Disorders
- Figure 5-1: TIGIT Inhibitor – Proposed Mechanism of Action
- Figure 5-2: TIGIT Inhibitor – Mechanism of Action
- Figure 6-1: Binding Efficacy of Monoclonal Antibody
- Figure 6-2: Binding Efficacy of Bispecific Antibodies
- Figure 6-3: Advantages of Small Molecule Drugs over Therapeutic Antibodies
- Figure 7-1: Tiragolumab - SKYSCRAPPER08 Phase-III Trial Initiation & Completion Year
- Figure 8-1: Global – TIGIT Inhibitors Clinical Trials by Company, 2022
- Figure 8-2: Global – TIGIT Inhibitors Clinical Trials by Country, 2022
- Figure 8-3: Global – TIGIT Inhibitors Clinical Trials by Patient Segment, 2022
- Figure 10-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 10-2: Global – TIGIT Inhibitor Market Drivers
- Figure 10-3: Stages of Drug Development

I would like to order

Product name: Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022

Product link: <https://marketpublishers.com/r/GCE9E151C93EEN.html>

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCE9E151C93EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970